Tumor PD-L1 expression levels were < 1% in 99 (46.7%) and 64 (45.4%) patients; 1–49% in 67 (31.6%) and 56 (39.7%); and ≥ 50% in 19 (9.0%) and 10 (7.1%), respectively. This evidence concerns the gene CD274 and neoplasm.